Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4

PHASE4TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

March 31, 2016

Conditions
Chronic Kidney Disease
Interventions
DRUG

Sevelamer carbonate

Sevelamer carbonate 1,600 mg three times daily with meals

DRUG

Calcium acetate

Calcium acetate 1,334 mg three times daily with meals for 12 weeks

Trial Locations (1)

12208

Albany Medical Center South Clinical Campus, Albany

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Albany Medical College

OTHER

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Albany College of Pharmacy and Health Sciences

OTHER

NCT01277497 - Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4 | Biotech Hunter | Biotech Hunter